Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elvitegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.89 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elvitegravir SCHEMBL13225651 | 0.94 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726251 | 0.94 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726252 | 0.94 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 0.94 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050769 | 0.94 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050765 | 0.94 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1045112 | 0.90 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL3245266 | 0.90 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL3118267 | 0.90 | METTL3 (0.85) | METTL3MAPTGAATP53CFD | |
| Elvitegravir SCHEMBL31577400 | 0.90 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197847-B1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVE FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143427-A1 | 4-Oxoquinoline derivatives | CYP3A4, PIK3CA, CYP3A5 | METTL3 2275/4885PLA2G4A 2963/4885MAPT 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.